Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO

Posted by |2020-03-31T11:51:11-07:00March 31st, 2020|

Hunter Smith, chief financial officer of Rhythm Pharmaceuticals (NASDAQ: RYTM), has been appointed interim CEO. He takes the place of Keith Gottesdiener, who announced in January that he planned to leave his executive positions and the board of directors after Rhythm submitted a new drug application for setmelanotide. The application was filed with the FDA […]

Viracta Adds Nordic Nanovector’s Lisa Rojkjaer as Chief Medical Officer

Posted by |2020-03-30T14:21:28-07:00March 30th, 2020|

Viracta Therapeutics has appointed Lisa Rojkjaer as its chief medical officer to oversee the clinical-stage precision oncology company’s efforts to advance treatments targeting virus-associated cancers. Rojkjaer, who will start with the company on May 1, most recently served in the same role at Nordic Nanovector, a precision oncology company in Oslo, Norway. Previously she held […]

San Diego Biotech Entrepreneurs, Innovation Lead to “Maturing” Ecosystem

Posted by |2020-03-30T02:00:59-07:00March 30th, 2020|

The local biotech ecosystem is growing up thanks to its innovative science and collaborative ecosystem, advantages that put it nearly on par with the nation’s top life science regions, according to industry veterans. San Diego has long been considered a second-tier primary biopharma hub in terms of number of companies and venture capital raised, falling […]

Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance

Posted by |2020-03-29T03:30:08-07:00March 27th, 2020|

Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one. Sanofi (NYSE: SNY) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: TBIO), […]

Fusion Pharmaceuticals Taps James O’Leary as Chief Medical Officer

Posted by |2020-03-26T17:15:59-07:00March 26th, 2020|

Clinical-stage oncology company Fusion Pharmaceuticals has appointed James O’Leary as its chief medical officer. Fusion is developing new radiopharmaceuticals—pharmaceutical drugs containing radioactive isotopes—to treat a range of types of cancer. O’Leary’s experience includes roles at biotechs including ImmunoGen (NASDAQ: IMGN), Idera Pharmaceuticals (NASDAQ: IDRA), Array Biopharma, and Deciphera (NASDAQ: DCPH), and pharma companies including Takeda […]

Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel

Posted by |2020-03-25T23:52:57-07:00March 25th, 2020|

Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference. The event is produced by EBD Group, […]

Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic

Posted by |2020-03-25T02:00:50-07:00March 25th, 2020|

Kallyope, one of New York’s best funded biotechs, has secured more than $100 million to move two of its programs into the clinic—including its most advanced, an experimental drug designed to treat obesity. The company was founded in 2015 with $44 million to leverage new learnings about the “gut-brain axis”—pings of communication between our guts […]

Genprex Adds Chief Strategy Officer, Chief Operating Officer to C-Suite

Posted by |2020-03-23T15:59:58-07:00March 23rd, 2020|

Gene therapy company Genprex (NASDAQ: GNPX) has added two new executives to its management team: Catherine Vaczy as chief strategy officer and Michael Redman as chief operating officer. Both are executive vice presidents. Vaczy most recently provided strategic advisory services to early stage biotechnology companies. Previously she co-founded and served for a decade on the […]

UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity

Posted by |2020-03-23T03:30:08-07:00March 20th, 2020|

A group of scientists and physicians at UC San Diego Health and the UCSD School of Medicine has arranged a partnership with five diagnostics markers that it says will bring the health system’s capacity to test for coronavirus to as many as 1,500 tests daily sometime in early April. Amid a lack of available tests […]

Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies

Posted by |2020-03-20T00:46:57-07:00March 20th, 2020|

Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic. To enhance its chances of success, the Emeryville, CA-based company has struck an agreement to work with Lyell Immunopharma, another San Francisco Bay Area […]

How San Diego Biotech Leaders Are Adapting to Coronavirus Concerns

Posted by |2020-03-18T23:32:57-07:00March 18th, 2020|

Three hundred Takeda employees from the Japanese pharma giant’s California research center have been working from home for 10 days straight. Neurocrine Biosciences, one of the few commercial-stage biotechs in town, is working to ensure the animals housed in its vivarium are appropriately minded. Ciara Kennedy, CEO of clinical-stage antifungal therapy developer Amplyx, is facing […]

Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer

Posted by |2020-03-17T20:50:23-07:00March 17th, 2020|

Morphic Therapeutic (NASDAQ: MORF) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical research at Acceleron Pharma (NASDAQ: XLRN), where he oversaw the design and execution of clinical trials including late-stage development work on luspatercept, a drug the FDA approved last year for patients with the […]
Go to Top